HOLX Quote, Financials, Valuation and Earnings

Danaher Corp. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 15%. Hologic, Inc.'s return on equity of 11.59% beat Danaher Corp.'s return on equity of 6.87%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 1.99%. On the other hand Danaher Corp. has an analysts' consensus of $255.67 which suggests that it could grow by 11.91%. Given that Danaher Corp. has higher upside potential than Hologic, Inc., analysts believe Danaher Corp. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.801%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher Corp. offers a yield of 0.54% to investors and pays a quarterly dividend of $0.32 per share. Hologic, Inc. pays -- of its earnings as a dividend. Danaher Corp. pays out 20.42% of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic, Inc. quarterly revenues are $1B, which are smaller than Danaher Corp. quarterly revenues of $6.1B. Hologic, Inc.'s net income of $187.3M is lower than Danaher Corp.'s net income of $908M. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.21x while Danaher Corp.'s PE ratio is 47.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.16x versus 6.78x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis, Inc. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 21.11%. Hologic, Inc.'s return on equity of 11.59% beat Nuwellis, Inc.'s return on equity of -1004.06%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 1.99%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 19643.61%. Given that Nuwellis, Inc. has higher upside potential than Hologic, Inc., analysts believe Nuwellis, Inc. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.165, suggesting its less volatile than the S&P 500 by 116.484%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.

Hologic, Inc. quarterly revenues are $1B, which are larger than Nuwellis, Inc. quarterly revenues of $2.2M. Hologic, Inc.'s net income of $187.3M is higher than Nuwellis, Inc.'s net income of $468K. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.21x while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.16x versus 0.63x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 7.29%. Hologic, Inc.'s return on equity of 11.59% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 1.99%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Phibro Animal Health Corp. has higher upside potential than Hologic, Inc., analysts believe Phibro Animal Health Corp. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Hologic, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic, Inc. quarterly revenues are $1B, which are larger than Phibro Animal Health Corp. quarterly revenues of $363.9M. Hologic, Inc.'s net income of $187.3M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.21x while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.16x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 17.85% compared to Hologic, Inc.'s net margin of 14.58%. Hologic, Inc.'s return on equity of 11.59% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Hologic, Inc. has a consensus price target of $76.50, signalling upside risk potential of 1.99%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $619.96 which suggests that it could grow by 6.81%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Hologic, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Hologic, Inc..

Hologic, Inc. has a beta of 0.703, which suggesting that the stock is 29.745% less volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.144%.

Hologic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.43 per share. Hologic, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic, Inc. quarterly revenues are $1B, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Hologic, Inc.'s net income of $187.3M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Hologic, Inc.'s price-to-earnings ratio is 30.21x while Thermo Fisher Scientific, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic, Inc. is 4.16x versus 5.04x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.